Cutaneous Side Effects of Innovative Cancer Therapies

Targeted therapies become increasingly used in oncology. The most frequent used are EGFR- and multikinase-inhibitors as well as capecitabine and in future BRAF-inhibitors. By targeting signalling pathways very often normal tissues are effected and cutaneous side effects develop. EGFR-inhibitors induce mostly papulous exanthema, as do multikinase-inhibitors, but to a smaller amount. Capecitabine induces severe hand-foot syndrome. These side effects and their management to be started together with oncologic treatment are discussed here.